Karyopharm Therapeutics Inc revenue growth has been varied year-over-year.

What is KPTI's revenue growth rate?

Historical revenue data is available for Karyopharm Therapeutics Inc to analyze growth trends.

How fast is KPTI earnings growing?

Earnings growth data is available for Karyopharm Therapeutics Inc analysis.

What is KPTI's profit margin?

Profit margin data is available for Karyopharm Therapeutics Inc.

KPTI Revenue & Earnings Growth Analysis 2026 - Is Karyopharm Therapeutics Inc Growing?

Growth Summary

Karyopharm Therapeutics Inc (KPTI) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.

Over the past 4 years, Karyopharm Therapeutics Inc has achieved a revenue compound annual growth rate (CAGR) of 7.7%, while earnings have grown at -21.0% CAGR.

Latest Revenue

$145.24M

Net Income

$-76422000.00

5-Year Revenue CAGR

7.7%

4 years of data

Net Margin

N/A

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Karyopharm Therapeutics Inc

The chart above illustrates Karyopharm Therapeutics Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Karyopharm Therapeutics Inc's business.

Profit Margin Trends

How efficiently Karyopharm Therapeutics Inc converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Karyopharm Therapeutics Inc retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (N/A%): Final profit after all expenses

Future Growth Outlook

Analyst estimates and forward-looking indicators

EPS Estimate 2026

$-4.78

Current: $-0.63

EPS Estimate 2027

$-4.37

-8.6% expected growth

Price Target

$11.00

Analyst consensus

What Analysts Are Saying

Wall Street analysts project Karyopharm Therapeutics Inc to continue growing earnings in the coming year. The consensus analyst rating is 4.1667 based on 6 analysts.

Growth Analysis Conclusion

Based on our comprehensive analysis, Karyopharm Therapeutics Inc (KPTI) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:, 7.7% CAGR over 4 years
Profitability: shows the company is investing in growth over short-term profits
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Karyopharm Therapeutics Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.